ArriVent BioPharma, Inc.
AVBP
6 insider filings · Latest: Feb 2, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Dec 10, 2025 | Feb 3 9:05 PM | HILLHOUSE INVESTMENT MANAGEMENT, LTD.10% Owner | Sale | 555,555 | $23.37 | $13.0M | 3,929,117(I) | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | Feb 5 1:44 AM | Robin LachapelleChief Operating Officer | Grant/Award | 130,000 | $22.67 | 130,000(D) | View → |
| Feb 2, 2026 | Feb 5 1:43 AM | Stuart LutzkerDirector, President of R&D | Grant/Award | 150,000 | $22.67 | 150,000(D) | View → |
| Feb 2, 2026 | Feb 5 1:41 AM | Winston KungChief Financial Officer | Grant/Award | 140,000 | $22.67 | 140,000(D) | View → |
| Feb 2, 2026 | Feb 5 1:40 AM | Zhengbin YaoDirector, President and CEO | Grant/Award | 550,000 | $22.67 | 550,000(D) | View → |
| Feb 2, 2026 | Feb 5 1:39 AM | James Paul KastenmayerGeneral Counsel | Grant/Award | 130,000 | $22.67 | 130,000(D) | View → |